Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study

Guilan Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Huo(Chinese Academy of Medical Sciences & Peking Union Medical College), Chao Fu(Wuhan No.1 Hospital), Peipei Zhou(John Brown University), Yuan Wang(Sichuan University), Yu Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Zheng Zhang(Xi'an Jiaotong University), Wenwen Duan, Shikun Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenjia Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College)
European Journal of Nuclear Medicine and Molecular Imaging
March 26, 2022
Cited by 39


Related Papers